Bioconversion

Aldehyde dehydrogenase 2 protects human umbilical vein endothelial cells against oxidative damage and increases endothelial nitric oxide production to reverse nitroglycerin tolerance

X. Y. Hu, Fang, Q., Ma, D., Jiang, L., Yang, Y., Sun, J., Yang, C., Wang, J. S., Hu, X. Y., Fang, Q., Ma, D., Jiang, L., Yang, Y., Sun, J., Yang, C., and Wang, J. S., Aldehyde dehydrogenase 2 protects human umbilical vein endothelial cells against oxidative damage and increases endothelial nitric oxide production to reverse nitroglycerin tolerance, vol. 15, p. -, 2016.

Medical nitroglycerin (glyceryl trinitrate, GTN) use is limited principally by tolerance typified by a decrease in nitric oxide (NO) produced by biotransformation. Such tolerance may lead to endothelial dysfunction by inducing oxidative stress. In vivo studies have demonstrated that aldehyde dehydrogenase 2 (ALDH2) plays important roles in GTN biotransformation and tolerance. Thus, modification of ALDH2 expression represents a potentially effective strategy to prevent and reverse GTN tolerance and endothelial dysfunction.

Subscribe to Bioconversion